Assessment of Needs
In this webinar, we will first provide an overview of the microbiome and review its role in human health and disease. We will then discuss both previous and new data demonstrating the critical role of the microbiome in HIV transmission and pathogenesis, and will what mechanisms underlie the impact of the microbiome in HIV. We will then discuss novel data for the role of the microbiome in COVID-19 disease, and how the microbiome may contribute to both acute disease, disease severity, and chronic COVID-19 symptoms. Finally, we will go over current and future strategies for manipulating the microbiome.
On completion of this webinar, learners will be able to:
- Explain what the microbiome is and how it can impact human health
- Identify the mechanisms that allow the microbiome to impact HIV transmission and pathogenesis
- Describe the potential role for the microbiome in COVID-19 disease
- List potential interventions that can promote a healthy microbiome and decrease disease
Who Should Attend
This webinar is designed for clinical decision makers who are actively involved in HIV care and research.
This activity is also relevant for nursing professionals, physician assistants, pharmacists, and other health care professionals.
Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.
Registration closes on Tuesday, July 27, 2021, 9:00 AM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at firstname.lastname@example.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Dr Klatt has served as a consultant for Takeda, Seres Therapeutics, and Clinical Care Options. (Updated 04/21/21)
All relevant financial relationships have been mitigated.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
These activities are eligible for ANCC credit, see final CNE activity announcement for specific details.
Accreditation Council for Pharmacy Education logoThese activities are eligible for ACPE credit, see final CPE activity announcement for specific details.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc.
Merck & Co., Inc.
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at email@example.com or 415-544-9400.